Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

D. Lee (), A. Amadi, J. Sabater, J. Ellis, H. Johnson, S. Kotapati, S. McNamara, A. Walker, M. Cooper, K. Patterson, N. Roskell and Y. Meng
Additional contact information
D. Lee: BresMed Health Solutions
A. Amadi: Bristol-Myers Squibb Pharmaceuticals
J. Sabater: Bristol-Myers Squibb
J. Ellis: Bristol-Myers Squibb Pharmaceuticals
H. Johnson: Helen Johnson Consulting Ltd
S. Kotapati: Bristol-Myers Squibb
S. McNamara: University of Sheffield
A. Walker: Salus Alba
M. Cooper: BresMed Health Solutions
K. Patterson: BresMed Health Solutions
N. Roskell: BresMed Health Solutions
Y. Meng: BresMed Health Solutions

PharmacoEconomics - Open, 2019, vol. 3, issue 1, No 5, 43-54

Abstract: Abstract Background Nivolumab with ipilimumab (the Regimen) is the first immuno-oncology combination treatment to demonstrate long-term clinical benefit for advanced melanoma patients. We evaluated the cost effectiveness of the Regimen in this population, with and without the availability of overall survival (OS) data. Methods A partitioned survival model and a Markov state-transition model were developed to estimate the lifetime costs and benefits of the Regimen versus ipilimumab. These models were built with and without the availability of OS data, as only progression-free survival data were available from the head-to-head, phase III trial against ipilimumab at the time of the National Institute for Health and Care Excellence (NICE) submission. Patient utilities and resource use data were sourced from trial data or the literature. Results Incremental cost-effectiveness ratios (ICERs) and absolute costs were similar between the models with and without OS data, but the model with OS data generated more than 1 additional quality-adjusted life-year (QALY) across both treatment arms. In both models, based on list prices, the Regimen was the most cost-effective treatment. Conclusions The analyses show that the Regimen is a cost-effective treatment for advanced melanoma patients in England, and methods to overcome the lack of OS can give reasonable estimates of QALYs gained and ICERs.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-018-0080-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:3:y:2019:i:1:d:10.1007_s41669-018-0080-5

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-018-0080-5

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().